INO•benzinga•February 12, 2025 at 01:04 PM

INOVIO Announces Phase 1/2 Trial Results Of INO-3107 For Recurrent Respiratory Papillomatosis With 81% Of Patients Requiring Fewer Surgeries; Plans BLA Submission In Mid-2025 For FDA Accelerated Approval, Aiming To Achieve First US DNA Medicine Approval

No summary available.

Read the full article from the original source for complete details and context.

Article published on February 12, 2025 by benzinga